Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Q3 2026 Results
Friday, October 30, 2026
13:30 - 14:30 CET (8:30am - 9:30am EDT)
Management presentation followed by a Q&A session with the financial community.
Aide-mémoire available.
Press Releases
Upcoming Events
30Oct
Third quarter 2026 results
Third quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on October 30, 2026. The presentation will be followed by a Q&A session.
13:30 - 14:30 CET (8:30am - 9:30am EDT)
Quarterly results
28Jan
Fourth quarter & full year 2026 results
Fourth quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on January 28, 2027. The presentation will be followed by a Q&A session.
TBD CET (TBD EST)
Quarterly results
23Apr
First quarter 2027 results
First quarter 2027 results will be reviewed by management during a live audio webcast with the financial community on April 23rd, 2027. The presentation will be followed by a Q&A session.
TBD CEST (TBD EDT)
Quarterly results
Dividend (in dollars) per ADR (½ share)
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00